Elizabeth Terry-Kantor

Ms. Elizabeth Terry-Kantor

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Molecular Cell
Verified
Journal Article
Closed access
SFSaranna Fanning
Saranna Fanning
AHAftabul Haque
Aftabul Haque
TIthibaut imberdis
thibaut imberdis
VBValeriya Baru
Valeriya Baru
MBM. Inmaculada Barrasa
M. Inmaculada Barrasa
DSDennis Selkoe
Dennis Selkoe

23 September 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
TIthibaut imberdis
thibaut imberdis
JNJoseph Negri
Joseph Negri
NRNagendran Ramalingam
Nagendran Ramalingam
ETElizabeth Terry-Kantor
Elizabeth Terry-Kantor
GHGary P. H. Ho
Gary P. H. Ho
UDUlf Dettmer
Ulf Dettmer
Significance: Misfolding and accumulation of the protein α-synuclein (αS) inside nerve cells characterize Parkinson’s disease (PD) and related brain diseases, for which no disease-modifying therapies exist. Robust cell models are needed that recapitulate abnormal αS folding/accumulation in real time, especially for compound screening. We took advantage of the engineered αS “3K” (E35K+E46K+E61K) mutation, which amplifies the familial PD-causing E46K and readily forms round inclusions. We rescued the inclusions with known αS modulators and then screened a ∼2,000-compound library. We identified the potential therapeutic target stearoyl-CoA desaturase; its inhibition cleared αS inclusions, in accord with the effects of conditioning in saturated fatty acids. We propose a model for how fatty acids serve as key modulators of cellular αS homeostasis.

19 June 2017 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
UDUlf Dettmer
Ulf Dettmer
NRNagendran Ramalingam
Nagendran Ramalingam
VSVictoria E. von Saucken
Victoria E. von Saucken
TKTae-Eun Kim
Tae-Eun Kim
ANAndrew J. Newman
Andrew J. Newman
DSDennis Selkoe
Dennis Selkoe
α-Synuclein (αS) forms round cytoplasmic inclusions in Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Evidence suggests a physiological function of αS in vesicle trafficking and release. In contrast to earlier tenets, recent work indicates that αS normally exists in cells in a dynamic equilibrium between monomers and tetramers/multimers. We engineered αS mutants incapable of multimerization, leading to excess monomers at vesicle membranes. By EM, such mutants induced prominent vesicle clustering, leading to round cytoplasmic inclusions. Immunogold labeling revealed abundant αS intimately associated with vesicles of varied size. Fluorescence microscopy with marker proteins showed that the αS-associated vesicles were of diverse endocytic and secretory origin. An αS ‘3K’ mutant (E35K + E46K + E61K) that amplifies the PD/DLB-causing E46K mutation induced αS-rich vesicle clusters resembling the vesicle-rich areas of Lewy bodies, supporting pathogenic relevance. Mechanistically, E46K can increase αS vesicle binding via membrane-induced amphipathic helix formation, and ‘3K’ further enhances this effect. Another engineered αS variant added hydrophobicity to the hydrophobic half of αS helices, thereby stabilizing αS-membrane interactions. Importantly, substituting charged for uncharged residues within the hydrophobic half of the stabilized helix not only reversed the strong membrane interaction of the multimer-abolishing αS variant but also restored multimerization and prevented the aberrant vesicle interactions. Thus, reversible αS amphipathic helix formation and dynamic multimerization regulate a normal function of αS at vesicles, and abrogating multimers has pathogenic consequences.

Verified
Journal Article
Open access
PDF file
ETElizabeth Terry-Kantor
Elizabeth Terry-Kantor
ATArati Tripathi
Arati Tripathi
TIthibaut imberdis
thibaut imberdis
ZLZachary M. LaVoie
Zachary M. LaVoie
GHGary P. H. Ho
Gary P. H. Ho
UDUlf Dettmer
Ulf Dettmer
Genetic and biochemical evidence attributes neuronal loss in Parkinson’s disease (PD) and related brain diseases to dyshomeostasis of the 14 kDa protein α-synuclein (αS). There is no consensus on how αS exerts toxicity. Explanations range from disturbed vesicle biology to proteotoxicity caused by fibrillar aggregates. To probe these mechanisms further, robust cellular toxicity models are needed, but their availability is limited. We previously reported that a shift from dynamic multimers to monomers is an early event in αS dyshomeostasis, as caused by familial PD (fPD)-linked mutants such as E46K. Excess monomers accumulate in round, lipid-rich inclusions. Engineered αS ‘3K’ (E35K+E46K+E61K) amplifies E46K, causing a PD-like, L-DOPA-responsive motor phenotype in transgenic mice. Here, we present a cellular model of αS neurotoxicity after transducing human neuroblastoma cells to express yellow fluorescent protein (YFP)-tagged αS 3K in a doxycycline-dependent manner. αS-3K::YFP induction causes pronounced growth defects that accord with cell death. We tested candidate compounds for their ability to restore growth, and stearoyl-CoA desaturase (SCD) inhibitors emerged as a molecule class with growth-restoring capacity, but the therapeutic window varied among compounds. The SCD inhibitor MF-438 fully restored growth while exerting no apparent cytotoxicity. Our αS bioassay will be useful for elucidating compound mechanisms, for pharmacokinetic studies, and for compound/genetic screens.